- Home
- PCVX vs MIRM Comparison
PCVX vs MIRM Comparison
Compare PCVX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | MIRM |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCVX | MIRM |
|---|---|---|
| Price | $60.78 | $127.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $88.25 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.6M | 908.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.10 | $50.25 |
| 52 Week High | $65.00 | $126.00 |
Technical Indicators
Market Signals| Indicator | PCVX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 70.63 |
| Support Level | $42.30 | $88.92 |
| Resistance Level | $64.16 | N/A |
| Average True Range (ATR) | 2.56 | 5.85 |
| MACD | 0.95 | 1.64 |
| Stochastic Oscillator | 94.88 | 98.14 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.